Arabic Arabic English English French French German German
dark

Psychedelic Drug Headed to Pivotal Trial in Treatment-Resistant Depression

​The drug reportedly demonstrated significant improvement in patients at its highest dose of 25 mg, particularly in reducing the severity of depressive symptoms after three weeks. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Benefits of Flexible Packaging for Medical Devices Now Include Child Resistance

Next Post

Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting

Related Posts
Total
0
Share